Condition: Polyarticular Course Juvenile Idiopathic Arthritis · Sponsor: Alfasigma S.p.A.
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
This description comes directly from the study's public registry record.
Medical Information · 00800 7878 1345 · medicalinfo@alfasigma.com
Always discuss trial participation with your own doctor first.
| UZ Leuven | Leuven, Belgium | Recruiting |
| Vseobecna fakultni nemocnice v Praze | Prague, Czechia | Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| Charité - Campus Virchow-Klinikum | Berlin, Germany | Recruiting |
| Hamburger Zentrum fuer Kinder und Jugendrheumatologie | Hamburg, Germany | Recruiting |
| Pecsi Tudomanyegyetem Klinikai Kozpont | Pécs, Hungary | Recruiting |
| Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS | Genova, Italy | Recruiting |
| Centrum Medyczne Hipokrates S C Elzbieta I Grzegorz Grzesk | Bydgoszcz, Poland | Recruiting |
| MICS Centrum Medyczne Torun | Torun, Poland | Recruiting |
| ETG JustMed | Warsaw, Poland | Recruiting |
| Hospital Sant Joan de Deu | Barcelona, Spain | Recruiting |
| Bristol Royal Hospital for Children | Bristol, United Kingdom | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07554495